LDL1 change at 12 months (mg/dL)	Achievement of 12- month LDL goal	Potency Increase	Annual Adherence Rate
	Estimate (95% CI)	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Estimate (95% CI)
Age	0.08 (−0.18, 0.34)	0.99 (0.97, 1.00)	0.98 (0.96, 0.99)**	−0.001 (−0.003, 0.001)
Female gender	6.0 (1.5, 11)**	0.74 (0.56, 0.97)*	1.01 (0.77, 1.31)	−0.024 (−0.062, 0.014)
Black race	−1.1 (−7.0, 4.7)	0.95 (0.65, 1.39)	1.06 (0.75, 1.51)	−0.048 (−0.098, 0.003)
Other race	−1.2 (−12, 9.2)	0.72 (0.35, 1.46)	0.72 (0.37, 1.42)	−0.072 (−0.15, 0.008)
Income <50,000	1.4 (−3.2, 6.1)	1.02 (0.78, 1.33)	1.12 (0.87, 1.43)	0.010 (−0.025, 0.045)
Education less than college	−5.7 (−10, −1.4)*	1.41 (1.06, 1.88)*	1.03 (0.77, 1.36)	0.051 (0.016, 0.086)**
LDL at baseline	−0.61 (−0.68, −0.53)**	1.02 (1.01, 1.03)**	1.01 (1.001, 1.01)*	0.002 (0.001, 0.002)**
FRS at baseline	20 (−4.7, 45)	0.36 (0.075, 1.71)	2.16 (0.47, 9.9)	0.16 (−0.057, 0.37)
CAD diagnosis	−1.5 (−5.9, 2.9)	0.85 (0.64, 1.13)	0.94 (0.70, 1.27)	−0.028 (−0.066, 0.009)
No baseline medication	2.8 (−1.6, 7.1)	0.68 (0.52, 0.89)**	0.78 (0.59, 1.02)	−0.29 (−0.33, −0.25)**
Patient incentive arm	−2.5 (−8.2, 3.1)	1.37 (0.93, 2.00)	0.99 (0.65, 1.51)	0.092 (0.044, 0.14)**
Physician incentive arm	−4.8 (−10, 0.65)	1.27 (0.89, 1.82)	1.33 (0.92, 1.93)	0.055 (0.002, 0.11)*
Shared incentive arm	−9.8 (−15, −4.1)**	1.81 (1.29, 2.55)**	1.68 (1.14, 2.46)**	0.12 (0.072, 0.18)**
Medicaid	12 (−0.77, 25)	0.37 (0.15, 0.93)*	1.21 (0.61, 2.40)	0.001 (−0.10, 0.10)
Medicare	−0.60 (−5.6, 4.4)	1.00 (0.74, 1.34)	0.97 (0.72, 1.32)	−0.015 (−0.055, 0.025)
Uninsured	12 (3.3, 20)**	0.47 (0.26, 0.84)*	1.38 (0.83, 2.29)	−0.054 (−0.12, 0.011)
Visits per year	−0.15 (−0.64, 0.34)	1.00 (0.97, 1.04)	1.04 (1.01, 1.07)**	−0.001 (−0.005, 0.004)

^*p<0.05;

^**p<0.01

SI conversion factor: To convert cholesterol to mmol/L, multiply values by 0.0259

Abbreviations:

¹low-density lipoprotein

²Framingham Risk Score

³coronary artery disease

Notes: Models of trial outcomes on patient characteristics and incentive arms, with interactions between all patient characteristics and incentive arms. Estimates and 95% confidence intervals are reported for the models of LDL change and adherence rate, while odds ratios and 95% confidence intervals are reported for the models of LDL goal achievement and medication potency increase. The goal achievement model does not include interactions between payor and incentive arms, because the model would not converge when including these terms.